Kamada Announces a $10-$14 Million Extension of Canadian Supply Tender

Core Viewpoint - Kamada Ltd. has secured a two-year extension of a tender from Canadian Blood Services for the supply of four specialty plasma-derived products, valued between $10 million to $14 million, ensuring ongoing sales in the Canadian market from Q2-26 to Q1-28 [1][4]. Group 1: Company Performance and Financial Guidance - The tender extension is expected to secure ongoing sales of approximately $5 million to $7 million per year during the contract period [5]. - Kamada has reiterated its full-year 2025 revenue guidance of $178 million to $182 million and adjusted EBITDA guidance of $40 million to $44 million [2][5]. - The company projects double-digit growth in revenues and profitability for 2026, supported by its robust commercial portfolio and expansion of normal source plasma sales [2][5]. Group 2: Strategic Positioning and Future Outlook - The CEO of Kamada emphasized the company's leading position in the specialty plasma-derived products market in Canada and expressed confidence in the commercial potential of its AAT and specialty immunoglobulin portfolio in international markets [2][5]. - The company aims to pursue additional contracts in key strategic territories to enhance its market presence [2][5]. - Kamada's growth strategy includes organic growth from commercial activities, securing new business development opportunities, and expanding plasma collection operations to support revenue growth [3].